Topics
Low-grade glioma | Prognosis | MGMT methylation
Home > Publications > Topics > Low-grade glioma > Prognosis > MGMT methylation
Darlix A, Bady P, Deverdun J, Lefort K, Rigau V, Le Bars E,
Meriadec J, Carrière M, Coget A, Santarius T, Matys T,
Duffau H, Hegi ME.
Clinical value of
the MGMT
promoter methylation score in IDHmt low-grade glioma for
predicting benefit from temozolomide treatment.
Neurooncol
Adv. 2024 Dec 19;7(1):vdae224. doi:
10.1093/noajnl/vdae224. PMID:
40041202. Observational study. ˍ